Want to see IN:BLUEJET full AI Analyst Report?
Top Page
Blue Jet Healthcare Limited
(BLUEJET)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹695.00
▲(6.36% Upside)
Action:Reiterated
Date:07/11/26
The score is driven primarily by strong financial quality (high profitability and a very low-debt balance sheet) and bullish technical momentum (price above key moving averages with positive MACD). These positives are tempered by weaker recent operating momentum (FY2026 revenue decline and uneven cash flow/FCF conversion) and a demanding valuation (high P/E with low dividend yield).
Positive Factors
Conservative balance sheet
Extremely low leverage (debt-to-equity ~0.031 in FY2026) and a steadily expanding equity base provide durable financial flexibility. This reduces solvency risk, allows funding of compliance/capacity needs without reliance on external debt, and supports resilience through sector cycles.
Negative Factors
Sharp recent revenue decline
A material FY2026 revenue drop (~-20%) after prior growth suggests demand loss, adverse mix, or customer concentration risks. Sustained revenue weakness would reduce operating leverage, constrain reinvestment, and could erode the company’s ability to fund growth or defend margins over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage (debt-to-equity ~0.031 in FY2026) and a steadily expanding equity base provide durable financial flexibility. This reduces solvency risk, allows funding of compliance/capacity needs without reliance on external debt, and supports resilience through sector cycles.
Read all positive factors
Blue Jet Healthcare Limited (BLUEJET) vs. iShares MSCI India ETF (INDA)
Market Cap
₹107.73B
Dividend Yield0.21%
Average Volume (3M)39.82K
Price to Earnings (P/E)42.2
Beta (1Y)1.44
Revenue Growth-27.51%
EPS Growth-34.49%
CountryIN
Employees581
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)13.55
Shares Outstanding189,275,700
10 Day Avg. Volume20,637
30 Day Avg. Volume39,817
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)4.17
Price to Sales (P/S)5.99
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)17.22
Revenue Forecast (FY)₹11.68B
Blue Jet Healthcare Limited Business Overview & Revenue Model
Company Description
Blue Jet Healthcare Ltd. is a company that focuses on the manufacturing and supply of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), which are critical components for the pharmaceutical and healthcare sectors. Its produ...
How the Company Makes Money
null...
Blue Jet Healthcare Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
91
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.86B | 9.47B | 10.30B | 7.10B | 7.18B | 6.77B |
| Gross Profit | 3.94B | 4.14B | 5.69B | 3.89B | 2.70B | 2.97B |
| EBITDA | 2.95B | 2.94B | 4.24B | 2.48B | 2.43B | 2.69B |
| Net Income | 2.35B | 2.48B | 3.05B | 1.64B | 1.60B | 1.82B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 16.41B | 14.18B | 10.59B | 8.62B | 7.13B |
| Cash, Cash Equivalents and Short-Term Investments | 3.23B | 3.76B | 3.06B | 3.09B | 2.55B | 1.81B |
| Total Debt | 0.00 | 421.84M | 199.86M | 16.13M | 68.31M | 228.39M |
| Total Liabilities | -13.60B | 2.81B | 2.84B | 2.14B | 1.81B | 1.92B |
| Stockholders Equity | 13.60B | 13.60B | 11.33B | 8.45B | 6.81B | 5.22B |
Cash Flow | ||||||
| Free Cash Flow | 817.22M | 0.00 | -341.15M | 669.59M | 822.79M | 1.21B |
| Operating Cash Flow | 2.07B | 3.38B | 457.65M | 2.41B | 1.42B | 1.46B |
| Investing Cash Flow | -1.65B | -2.84B | -351.83M | -2.64B | -1.47B | -760.26M |
| Financing Cash Flow | -85.36M | -259.95M | -185.57M | -19.86M | -42.33M | -561.45M |
Blue Jet Healthcare Limited Technical Analysis
Neutral
653.45
Price Trends
585.04
Negative
525.06
Positive
490.45
Positive
Market Momentum
-2.07
Positive
43.01
Neutral
19.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Neutral. The current price of 653.45 is above the 20-day moving average (MA) of 586.72, above the 50-day MA of 585.04, and above the 200-day MA of 490.45, indicating a neutral trend. The MACD of -2.07 indicates Positive momentum. The RSI at 43.01 is Neutral, neither overbought nor oversold. The STOCH value of 19.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BLUEJET.
Blue Jet Healthcare Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹107.73B | 42.15 | ― | 0.21% | -27.51% | -34.49% | |
72 Outperform | ₹148.01B | 54.12 | ― | 0.52% | -6.72% | -22.67% | |
56 Neutral | ₹27.34B | 40.05 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹159.71B | 71.85 | ― | 0.32% | -3.41% | -56.45% | |
49 Neutral | ₹646.77B | 116.88 | ― | 0.13% | 9.83% | 5.07% | |
43 Neutral | ₹175.87B | -361.91 | ― | ― | 27.15% | 40.46% |
* General Sector Average
IN:BLUEJET
Blue Jet Healthcare Limited
570.15
-153.03
-21.16%
IN:BIOCON
Biocon Limited
393.50
29.69
8.16%
IN:CONCORDBIO
Concord Biotech Ltd.
1,442.50
-158.11
-9.88%
IN:DCAL
Dishman Carbogen Amcis Ltd.
171.40
-108.85
-38.84%
IN:SYNGENE
Syngene International Ltd.
389.45
-258.12
-39.86%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,552.40
-281.50
-15.35%
Blue Jet Healthcare Limited Corporate Events
Blue Jet Healthcare Raises ₹8,000 Million via Qualified Institutional Placement
Jul 9, 2026
Blue Jet Healthcare Limited has completed a qualified institutions placement of 15,810,276 equity shares with a face value of ₹2 each at an issue price of ₹506, including a premium of ₹504 per share. The placement, which ran from...
Blue Jet Healthcare Closes Qualified Institutions Placement, Allocates Over 15.8 Million Shares
Jul 9, 2026
Blue Jet Healthcare Limited has completed a qualified institutions placement of equity shares with eligible qualified institutional buyers, closing the issue on July 9, 2026 after receiving applications and funds in designated escrow accounts. The...
Blue Jet Healthcare posts FY26 earnings call transcript for investors
May 29, 2026
Blue Jet Healthcare Limited has released the transcript of its earnings call with analysts and investors discussing financial results for the quarter and full year ended March 31, 2026. The document, held on May 25, 2026 and now available on the c...
Blue Jet Healthcare Clears FY26 Results, Dividend and Rs 10 Billion Fund-Raise Plan
May 25, 2026
Blue Jet Healthcare’s board has approved the audited standalone financial results for the quarter and year ended 31 March 2026, with the statutory auditors issuing an unmodified opinion, underscoring the reliability of its reported performan...
Blue Jet Healthcare Clears FY26 Results, Dividend and ₹10 Billion Fundraise Plan
May 25, 2026
Blue Jet Healthcare’s board has approved the audited standalone financial results for the quarter and year ended 31 March 2026, with statutory auditors issuing an unmodified opinion, underscoring the company’s clean financial reporting...
Blue Jet Healthcare Clears FY26 Results, Dividend and Rs 10 Billion Fund-Raising Plan
May 25, 2026
Blue Jet Healthcare’s board has approved the audited standalone financial results for the quarter and year ended 31 March 2026, with statutory auditors KKC Associates LLP issuing an unmodified opinion, underscoring the company’s clean...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.